Drugs / HR19024
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05463432 | Aug 2022 → Oct 2024 | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HR19024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05463432 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT05463432 ↗ |